کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3923112 1253016 2009 14 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
پیش نمایش صفحه اول مقاله
Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks
چکیده انگلیسی

ContextAndrogen deprivation therapy (ADT) is increasingly used for the treatment of prostate cancer (PCa), even in clinical settings in which there is no evidence-based proof of prolonged overall survival (OS). ADT, however, may be associated with numerous side effects, including an increased therapy-related cardiovascular mortality.ObjectiveTo discuss different clinical settings in which ADT is currently used and to critically weigh the benefits of ADT against its possible side effects.Evidence acquisitionA MEDLINE search was conducted to identify original articles and review articles addressing the efficacy and side effects of ADT for the treatment of PCa. Keywords consisted of prostate cancer, hormonal therapy, adverse effects, radical prostatectomy, and radiotherapy. The articles with the highest level of evidence for the various examined end points were identified with the consensus of all authors and were reviewed.Evidence synthesisEven short-term use of ADT may lead to numerous side effects, such as osteoporosis, obesity, sarcopenia, lipid alterations, insulin resistance, and increased risk for diabetes and cardiovascular morbidity. Despite these side effects, ADT is commonly used in various clinical settings in which a clear effect on improved OS has not been shown.ConclusionsADT is associated with an increased risk of multiple side effects that may reduce quality of life and/or OS. Consequently, these issues should be discussed in detail with patients and their families before initiation of ADT. ADT should be used with knowledge of its potential long-term side effects and with possible lifestyle interventions, especially in settings with the highest risk–benefit ratio, to alleviate comorbidities.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Urology - Volume 55, Issue 1, January 2009, Pages 62–75
نویسندگان
, , , , , , , ,